Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy
Source: SeekingAlpha
2026-02-03 09:22:15 ET
More on Invivyd
- Invivyd: Why I'm Selling The CDTX Read-Through Rally
- Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination
- Invivyd, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Invivyd granted FDA fast track status for COVID therapy
- Invivyd prices $125M stock offering at $2.50 per share
Read the full article on Seeking Alpha
For further details see:
Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy
Invivyd Inc.
NASDAQ: IVVD
IVVD Trading
4.64% G/L:
$1.805 Last:
407,603 Volume:
$1.79 Open:
IVVD Latest News
March 05, 2026 07:03:00 am
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
March 05, 2026 07:01:00 am
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
IVVD Stock Data
$379,990,219
86,954,817
0.02%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
